Metoclopramide and nitrendipine are unable to enhance cytotoxicity of mitoxantrone in sensitive and resistant murine leukemias in vivo

Archivum Immunologiae et Therapiae Experimentalis

Volumn 45, Issue 2-3, 1997, Pages 249-253

  Potemski, Piotr ^a   Polakowski, Przedzisław ^a  

^a University Medical School   (Poland)

Author keywords

Metoclopramide; Mitoxantrone resistance; Murine leukemias; Nitrendipine

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CALCIUM ANTAGONIST; METOCLOPRAMIDE; MITOXANTRONE; NITRENDIPINE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA; LEUKEMIA L 1210; LEUKEMIA P 388; MALE; NONHUMAN; SURVIVAL TIME; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIUM CHANNEL BLOCKERS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; LEUKEMIA L1210; LEUKEMIA P388; MALE; METOCLOPRAMIDE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MITOXANTRONE; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; NITRENDIPINE; TUMOR STEM CELLS;

EID: 0030872674     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. CORBETT T. H., ROBERTS B. J., TRADER M. W., LASTER W. R. JR., GRISWOLD D. P. JR. and SCHABEL F. M. JR. (1982): Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat. Rev., 66, 1187 - 1200.
2. DALTON W. S. (1993): Drug resistance modulation in the laboratory and the clinic. Semin. Oncol., 20, 64 - 69.
3. FAULDS D., BALFOUR J. A., CHRISP P. and LANGTRY H. D. (1991): Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. Drugs, 41, 400 - 449.
4. FICHTNER I., BECKER M., LEMM M. and WINTERFELD G. (1990): Development of mitoxantrone-resistant P338 in vivo: approaches to overcome resistance. Oncology, 47, 508 - 515.
5. FORD J. M. and HAIT W. N. (1990): Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 42, 155 - 199.
6. GERAN R. I., GREENBERG N. H., MACDONALD M. M., SCHUMACHER A. M. and ABBOT B. J. (1972): Protocols for screening chemicals agents and natural products against animal tumors and other biological systems. Cancer Chemother. Rep., 3, 1 - 103.
7. KAMATH N., GRABOWSKI D., FORD J., KERRIGAN D., POMMIER Y. and GANAPATHI R. (1992): Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone. Biochem. Pharmacol., 44, 937 - 945.
8. LING V. (1992): P-glycoprotein and resistance to anticancer drugs. Cancer, 69, 2603 - 2609.
9. LYBAK S., WENNERBERG J., KJELLEN E. and PERO R. (1991): Dose schedule evaluation of metoclopramide as a potentiator of cisplatin and carboplatin treatments of xenografted squamous cell carcinomas of the head and neck. Anticancer Drugs, 2, 375 - 382.
10. PINKUS R. and GOLDMAN I. D. (1990): Evidence for impaired mitoxantrone and vinblastine binding in P388 murine leukemia cells with multidrug resistance. Biochem. Pharmacol., 40, 2625 - 2635.
11. SALFORD L. G., PERO R. W., AAS A. T. and BRUN A. (1992): Metoclopramide as a sensitizer of 1,3-bis(2-chloroethyl)-1-nitrosourea treatment of brain tumors in the rat. Anticancer Drugs, 3, 267 - 272.
12. TSURUO T., IIDA H., NOJIRI M., TSUKAGOSHI S. and SAKURAI Y. (1983): Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res., 43, 2905 - 2910.
13. TSURUO T., IIDA H., TSUKAGOSHI S. and SAKURAI Y. (1982): Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulim inhibitors. Cancer Res., 42, 4730 - 4733.
14. TYSON F. L., BROWN Y. M., WALKER D. M., BELINSKY S. A. and ANDERSON M. W. (1990): Inhibition of murine pulmonary metastases by cisplatinum in combination with metoclopramide. Proc. Am. Assoc. Cancer Res., 31, 388.